Above this, we have established a regularized DBN model that was able to predict key players of TRAIL susceptibility correctly and helped to identify XIAP to serve as a potential biomarker for TRAIL treatment responsiveness in mutBRAF melanoma. This evidence concerns the gene TNFSF10 and melanoma.